Date Time
Share
No deal Brexit could have detrimental impact for four million people in UK living with a rare disease
Experts have warned that a ‘no deal’ Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly specialised diagnosis and treatment.
Rare diseases are rare, and experts are rarer still. European Reference Networks were set up because no single country has the expertise or resources to cover all of the known rare diseases, which number in the thousands
E-Mail
Experts have warned that a no deal Brexit will result in the exclusion of the UK from the 24 European Reference Networks (ERNs) that were established to improve the care of patients bearing the lifelong burden of a rare disease, which require highly specialised diagnosis and treatment.
One in 17 UK citizens lives with a rare disease, which are defined as conditions that affect fewer than one in 2,000 people in the general population. A group of experts has written to
The Lancet highlighting their concerns about the detrimental impact a no deal Brexit will have on these individuals. Rare diseases are rare, and experts are rarer still, said Dr Marc Tischkowitz from the University of Cambridge, who helped coordinate the letter. European Reference Networks were set up because no single country has the expertise or resources to cover all of the known rare diseases, which number in the thousands. They ve played a pivotal role in harnessing the collective knowledge across
Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma
News provided by
Share this article
Share this article
NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN) added three different XPOVIO® (selinexor) combination regimens to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for previously treated multiple myeloma. The XPOVIO regimens added to the NCCN guidelines, include: (i) selinexor / bortezomib / dexamethasone (once-weekly) (SVd); (ii) selinexor / daratumumab / dexamethasone (SDd); and (iii) selinexor / pomalidomide / dexamethasone (SPd), which is an all-oral treatment regimen. Importantly, the once weekly SVd regimen received a Category 1 recommendat
HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.